60 Degrees Pharmaceuticals, Inc.
SXTP Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.87
KIRA · Stoqly’s AI analyst, in plain words
- 60 Degrees Pharmaceuticals, Inc. had $1.0M of revenue in fiscal 2025, up 65.5% on the year before.
- Its operating margin was −771.6%, up 827.3 pts: of every 100 in sales, about −772 is left after running the business.
- 60 Degrees Pharmaceuticals, Inc. lost $7.4M in fiscal 2025.
- Free cash flow was −$7.0M in fiscal 2025, −695.1% of revenue.
- 60 Degrees Pharmaceuticals, Inc. has $2.6M more cash than debt.
Market cap
$2.3M
P/E
—
Revenue
$1.0M
Net income
−$7.4M
Free cash flow
−$7.0M
Operating margin
−771.6%
60 Degrees Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+65.5%
Yes. Sales grew 65.5% last year.
Does it make a profit?
−732.5%
No. It lost money last year.
Does profit turn into cash?
−695.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What 60 Degrees Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- 60 DEGREES PHARMACEUTICALS, INC.
- CIK
- 0001946563
60 Degrees Pharmaceuticals, Inc. · SXTP
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $0.2M | $0.3M | $0.6M | $1.0M |
| Revenue growth | — | 13.6% | 139.6% | 65.5% |
| Net interest income | −$4.4M | $1.3M | — | — |
| Gross margin | −93.7% | −87.1% | 36.7% | 22.3% |
| Operating margin | −784.2% | −2,032.6% | −1,598.9% | −771.6% |
| Net income | −$6.2M | −$3.8M | −$7.9M | −$7.4M |
| Net margin | −2,769.6% | −1,484.9% | −1,307.9% | −732.5% |
| Diluted EPS | −$2.61 | −$59.18 | −$74.17 | −$11.73 |
| Cash | ||||
| Cash from operations | −$1.0M | −$4.5M | −$5.6M | −$6.8M |
| Capital expenditure | — | $0.1M | $0.1M | $0.1M |
| Free cash flow | — | −$4.6M | −$5.8M | −$7.0M |
| FCF margin | — | −1,814.1% | −946.7% | −695.1% |
| Share count change | — | −97.2% | 71.5% | 489.4% |
| Debt and strength | ||||
| Cash and short-term investments | $0.3M | $2.1M | $3.4M | $2.8M |
| Debt incl. finance leases | $16.9M | $0.2M | $0.2M | $0.2M |
| Shareholders' equity | −$23.6M | $4.9M | $4.0M | $3.5M |
| Current ratio | 0.0x | 2.6x | 3.3x | 2.7x |
| Interest coverage | −0.4x | −2.3x | −1,229.8x | −994.7x |
| Returns and quality | ||||
| Return on capital | — | −141.5% | −962.1% | −710.7% |
| Return on equity | — | — | −178.5% | −196.4% |
| Return on tangible equity | — | −84.5% | −217.4% | −242.7% |
| Piotroski F-score | — | 5 | 4 | 3 |
| Altman Z'' | −197.9 | −12.7 | −27.7 | −33.2 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
60 Degrees Pharmaceuticals, Inc. · SXTP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.87 a share, the company is worth $2.3M.
Source: SEC EDGAR XBRL filings (CIK 0001946563). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.